Break

The human gut microbiome has become a hot topic in the search for new therapeutics to solve unmet medical needs. As the world’s knowledge has expanded, the gut microbiome has been implicated in many conditions as far ranging as infectious disease to autism. In 2011, Rebiotix was founded to develop a microbiome-based drug to treat recurrent Clostridium difficile infection – a highly contagious disease of the gastrointestinal track – where standard of care therapeutics fall short. Join Lee Jones, UMN ChE ‘79, as she shares the journey and the science behind what is expected to be the first commercially available microbiome product in the world.